Skip to main content
. 2018 Dec 13;51(3):1180–1187. doi: 10.4143/crt.2018.532

Table 1.

Effect of NBN variants on prostate cancer risk

NBN variant Unselected prostate cancer cases
Familial prostate cancer cases
Control No./Total (%)
No./Total (%) OR (95% CI) p-value No./Total (%) OR (95% CI) p-value
657del5 74/5,189 (1.4) 2.5 (1.7-3.8) < 0.001 15/635 (2.4) 4.2 (2.3-7.8) < 0.001 35/6,152 (0.6)
R215W 13/5,189 (0.25) 1.3 (0.5-3.4) 0.762 2/635 (0.3) 1.6 (0.3-8.2) 0.889 6/3,122a) (0.2)
I171V 140/5,189 (2.7) 1.2 (0.9-1.5) 0.351 8/635 (1.3) 0.5 (0.3-1.1) 0.120 73/3,122a) (2.3)
E185Q (GG genotype) 2,207/5,189 (42.6) 1.0 (0.9-1.1) 0.994 270/634 (42.6) 1.0 (0.8-1.2) 0.982 2,617/6,152 (42.5)
E185Q (GC genotype) 2,389/5,189 (46.0) 1.0 (0.9-1.1) 0.565 287/634 (45.3) 1.0 (0.8-1.2) 0.952 2,798/6,152 (45.5)
E185Q (CC genotype) 593/5,189 (11.4) 0.9 (0.8-1.1) 0.379 77/518 (12.1) 1.0 (0.8-1.3) 0.954 737/6,152 (12.0)

OR, odds ratio; CI, confidence interval.

a)

For R215W and R215W variants 3,122 controls were only genotyped.